NEPHROLOGIE & THERAPEUTIQUE, ISSN 1769-7255, 12/2018, Volume 14, Issue 7, pp. 555 - 563
Expansion of extracellular volume is a treatment traditionally proposed to correct abnormalities of renal perfusion and prevent ischemic injury. However,...
ACUTE KIDNEY INJURY | NORMAL SALINE RESUSCITATION | SODIUM-BICARBONATE | Colloids | Hydroxyethylstarch | ACUTE LUNG INJURY | ACUTE-RENAL-FAILURE | Oncotic pressure | BLOOD-FLOW | Acute renal failure | FLUID RESUSCITATION | LACTATED RINGERS SOLUTION | Remplissage | Osmotic nephrosis | UROLOGY & NEPHROLOGY | HYDROXYETHYL STARCH 130/0.4 | OSMOTIC-NEPHROSIS | Animals | Kidney Diseases - etiology | Humans | Kidney - physiopathology | Plasma Substitutes - adverse effects
ACUTE KIDNEY INJURY | NORMAL SALINE RESUSCITATION | SODIUM-BICARBONATE | Colloids | Hydroxyethylstarch | ACUTE LUNG INJURY | ACUTE-RENAL-FAILURE | Oncotic pressure | BLOOD-FLOW | Acute renal failure | FLUID RESUSCITATION | LACTATED RINGERS SOLUTION | Remplissage | Osmotic nephrosis | UROLOGY & NEPHROLOGY | HYDROXYETHYL STARCH 130/0.4 | OSMOTIC-NEPHROSIS | Animals | Kidney Diseases - etiology | Humans | Kidney - physiopathology | Plasma Substitutes - adverse effects
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 08/2016, Volume 2016, Issue 8, p. CD001302
Background Ovarian hyperstimulation syndrome (OHSS) is a serious and potentially fatal complication of ovarian stimulation which affects 1% to 14% of all in...
Hydroxyethyl Starch Derivatives [administration & dosage] | INTRAVENOUS ALBUMIN | Injections, Intravenous | Humans | HYDROXYETHYL STARCH | Plasma Substitutes [administration & dosage] | Randomized Controlled Trials as Topic | OOCYTE MATURATION | Sperm Injections, Intracytoplasmic | MEDICINE, GENERAL & INTERNAL | Fertilization in Vitro | SYNDROME OHSS | HIGH-RISK | DOUBLE-BLIND | Serum Albumin [administration & dosage] | Female | IN-VITRO FERTILIZATION | GNRH AGONIST | IVF PATIENTS | Ovarian Hyperstimulation Syndrome [prevention & control] | ENDOTHELIAL GROWTH-FACTOR | Pregnancy | Hydroxyethyl Starch Derivatives - administration & dosage | Plasma Substitutes - administration & dosage | Serum Albumin - administration & dosage | Ovarian Hyperstimulation Syndrome - prevention & control | Pregnancy Rate
Hydroxyethyl Starch Derivatives [administration & dosage] | INTRAVENOUS ALBUMIN | Injections, Intravenous | Humans | HYDROXYETHYL STARCH | Plasma Substitutes [administration & dosage] | Randomized Controlled Trials as Topic | OOCYTE MATURATION | Sperm Injections, Intracytoplasmic | MEDICINE, GENERAL & INTERNAL | Fertilization in Vitro | SYNDROME OHSS | HIGH-RISK | DOUBLE-BLIND | Serum Albumin [administration & dosage] | Female | IN-VITRO FERTILIZATION | GNRH AGONIST | IVF PATIENTS | Ovarian Hyperstimulation Syndrome [prevention & control] | ENDOTHELIAL GROWTH-FACTOR | Pregnancy | Hydroxyethyl Starch Derivatives - administration & dosage | Plasma Substitutes - administration & dosage | Serum Albumin - administration & dosage | Ovarian Hyperstimulation Syndrome - prevention & control | Pregnancy Rate
Journal Article
Journal of Biomedical Materials Research Part A, ISSN 1549-3296, 07/2012, Volume 100A, Issue 7, pp. 1815 - 1822
Plasma expanders such as dextran and hydroxyethyl starch (HES) are important components of solutions designed to maintain vascular volume in the clinical...
hydroxyethyl starch | dextran | microfluidic hydrogel | perfusion | microvascular tissue engineering | PHYSIOLOGY | MATERIALS SCIENCE, BIOMATERIALS | MOLECULAR-WEIGHT | PERMEABILITY | ENGINEERING, BIOMEDICAL | ORGAN PRESERVATION | CYCLIC-AMP | BLOOD-CELL AGGREGATION | PHARMACOLOGY | FABRICATION | TUBES IN-VITRO | VASCULAR ENDOTHELIAL-CADHERIN | Tissue Scaffolds | Dextrans | Humans | Hydroxyethyl Starch Derivatives | Plasma Substitutes - pharmacology | Microvessels - drug effects | Cadherins | Microfluidics | Antigens, CD | Microvascular tissue engineering
hydroxyethyl starch | dextran | microfluidic hydrogel | perfusion | microvascular tissue engineering | PHYSIOLOGY | MATERIALS SCIENCE, BIOMATERIALS | MOLECULAR-WEIGHT | PERMEABILITY | ENGINEERING, BIOMEDICAL | ORGAN PRESERVATION | CYCLIC-AMP | BLOOD-CELL AGGREGATION | PHARMACOLOGY | FABRICATION | TUBES IN-VITRO | VASCULAR ENDOTHELIAL-CADHERIN | Tissue Scaffolds | Dextrans | Humans | Hydroxyethyl Starch Derivatives | Plasma Substitutes - pharmacology | Microvessels - drug effects | Cadherins | Microfluidics | Antigens, CD | Microvascular tissue engineering
Journal Article
Journal of Infusion Nursing, ISSN 1533-1458, 05/2015, Volume 38, Issue 3, pp. 217 - 222
Oxygen delivery capacity during profoundly anemic conditions depends on bloodʼs oxygen-carrying capacity and cardiac output. Oxygen-carrying blood substitutes...
microvascular perfusion | blood transfusion | oxygen transport | oxygen delivery | microcirculation | hemorrhage | transfusion alternatives | Anemia - therapy | Erythrocyte Transfusion | Hemorrhage - therapy | Humans | Oxygen - blood | Plasma Substitutes - pharmacology
microvascular perfusion | blood transfusion | oxygen transport | oxygen delivery | microcirculation | hemorrhage | transfusion alternatives | Anemia - therapy | Erythrocyte Transfusion | Hemorrhage - therapy | Humans | Oxygen - blood | Plasma Substitutes - pharmacology
Journal Article
Journal of Critical Care, ISSN 0883-9441, 10/2016, Volume 35, pp. 75 - 83
Gelatin is a widely used synthetic colloid resuscitation fluid. We undertook a systematic review and meta-analysis of adverse effects in randomized and...
Renal insufficiency | Anaphylaxis | Adverse effects | Plasma substitutes | Colloids | Bleeding | ACUTE KIDNEY INJURY | HYPOVOLEMIC SHOCK | HYDROXYETHYL STARCH | MODIFIED FLUID GELATIN | RINGERS SOLUTION | INTENSIVE-CARE | CARDIAC-SURGERY | HEMOSTATIC CHANGES | CRITICALLY-ILL PATIENTS | VOLUME REPLACEMENT | CRITICAL CARE MEDICINE | Fluid Therapy | Gelatin - administration & dosage | Hospital Mortality | Gelatin - adverse effects | Humans | Isotonic Solutions - administration & dosage | Hypovolemia - mortality | Isotonic Solutions - adverse effects | Hypovolemia - therapy | Plasma Substitutes - adverse effects | Albumin | Blood transfusion | Analysis
Renal insufficiency | Anaphylaxis | Adverse effects | Plasma substitutes | Colloids | Bleeding | ACUTE KIDNEY INJURY | HYPOVOLEMIC SHOCK | HYDROXYETHYL STARCH | MODIFIED FLUID GELATIN | RINGERS SOLUTION | INTENSIVE-CARE | CARDIAC-SURGERY | HEMOSTATIC CHANGES | CRITICALLY-ILL PATIENTS | VOLUME REPLACEMENT | CRITICAL CARE MEDICINE | Fluid Therapy | Gelatin - administration & dosage | Hospital Mortality | Gelatin - adverse effects | Humans | Isotonic Solutions - administration & dosage | Hypovolemia - mortality | Isotonic Solutions - adverse effects | Hypovolemia - therapy | Plasma Substitutes - adverse effects | Albumin | Blood transfusion | Analysis
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 03/2011, Volume 51, Issue 3, pp. 292 - 300
Hypovolemia from a range of etiologies can lead to severe morbidity and mortality unless blood volume and tissue perfusion are restored. The treatment of...
Albumin | colloids | pharmacovigilance | safety | PREKALLIKREIN ACTIVATOR | ACUTE-RENAL-FAILURE | IN-VITRO | IMPAIR HEMOSTASIS | HUMAN-ALBUMIN | PHARMACOLOGY & PHARMACY | INCREASE BLOOD-LOSS | CREUTZFELDT-JAKOB-DISEASE | HYDROXYETHYL STARCH 130/0.4 | ELDERLY-PATIENTS | TRANSFUSION REQUIREMENTS | Plasma Substitutes - therapeutic use | Hypovolemia - drug therapy | Colloids | Glycoproteins - therapeutic use | Humans | Glycoproteins - adverse effects | Serum Albumin, Human | Serum Albumin - adverse effects | Serum Albumin - therapeutic use | Blood Coagulation Disorders - drug therapy | Animals | Renal Insufficiency - physiopathology | Renal Insufficiency - drug therapy | Blood Coagulation Disorders - physiopathology | Hypovolemia - etiology | Plasma Substitutes - adverse effects | Shock | Intravenous therapy | Care and treatment | Research | Health aspects | Plasma | Blood
Albumin | colloids | pharmacovigilance | safety | PREKALLIKREIN ACTIVATOR | ACUTE-RENAL-FAILURE | IN-VITRO | IMPAIR HEMOSTASIS | HUMAN-ALBUMIN | PHARMACOLOGY & PHARMACY | INCREASE BLOOD-LOSS | CREUTZFELDT-JAKOB-DISEASE | HYDROXYETHYL STARCH 130/0.4 | ELDERLY-PATIENTS | TRANSFUSION REQUIREMENTS | Plasma Substitutes - therapeutic use | Hypovolemia - drug therapy | Colloids | Glycoproteins - therapeutic use | Humans | Glycoproteins - adverse effects | Serum Albumin, Human | Serum Albumin - adverse effects | Serum Albumin - therapeutic use | Blood Coagulation Disorders - drug therapy | Animals | Renal Insufficiency - physiopathology | Renal Insufficiency - drug therapy | Blood Coagulation Disorders - physiopathology | Hypovolemia - etiology | Plasma Substitutes - adverse effects | Shock | Intravenous therapy | Care and treatment | Research | Health aspects | Plasma | Blood
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2017, Volume 7, Issue 1, pp. 843 - 12
Artificial plasma expanders (PEs) are widely used in modern transfusion medicine. PEs do not contain components of the coagulation system, so their infusion in...
THROMBIN GENERATION | IN-VITRO | BLOOD-LOSS | MULTIDISCIPLINARY SCIENCES | DISSEMINATED INTRAVASCULAR COAGULATION | CLOT GROWTH | MASSIVE TRANSFUSION | HEMODILUTION | TRAUMA-INDUCED COAGULOPATHY | PROCOAGULANT ACTIVITY | PLATELET REACTIVITY | Plasma | Thrombin | pH effects | Clotting | Spatial discrimination | Coagulation
THROMBIN GENERATION | IN-VITRO | BLOOD-LOSS | MULTIDISCIPLINARY SCIENCES | DISSEMINATED INTRAVASCULAR COAGULATION | CLOT GROWTH | MASSIVE TRANSFUSION | HEMODILUTION | TRAUMA-INDUCED COAGULOPATHY | PROCOAGULANT ACTIVITY | PLATELET REACTIVITY | Plasma | Thrombin | pH effects | Clotting | Spatial discrimination | Coagulation
Journal Article
Artificial Cells, Nanomedicine, and Biotechnology, ISSN 2169-1401, 12/2019, Volume 47, Issue 1, pp. 73 - 82
Compromised microcirculation and endothelial dysfunction are hallmarks of sickle cell disease (SCD). EAF PEG Haemoglobin (Hb) and EAF PEG Albumin (Alb)...
tempo | plasma expanders | anti vaso-occlusion | EAF PEGylation | sickle cell disease | HEMOGLOBIN | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | VOLUME | EXTREME HEMODILUTION | FLOW | OXYGEN | CARBON-MONOXIDE | TRANSFUSION | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | ALBUMIN | POLYETHYLENE-GLYCOL | BLOOD
tempo | plasma expanders | anti vaso-occlusion | EAF PEGylation | sickle cell disease | HEMOGLOBIN | MATERIALS SCIENCE, BIOMATERIALS | ENGINEERING, BIOMEDICAL | VOLUME | EXTREME HEMODILUTION | FLOW | OXYGEN | CARBON-MONOXIDE | TRANSFUSION | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | ALBUMIN | POLYETHYLENE-GLYCOL | BLOOD
Journal Article
Minerva Anestesiologica, ISSN 0375-9393, 07/2011, Volume 77, Issue 7, pp. 669 - 670
Journal Article
Transfusion Medicine, ISSN 0958-7578, 02/2008, Volume 18, Issue 1, pp. 28 - 39
summary The objective of this study was to further explore the safety of Hemospan® (Sangart Inc., San Diego, CA, USA), an oxygen‐carrying plasma expander. The...
MP4 | blood substitutes | haemoglobin | PEG | haemoglobin‐based oxygen carriers | spinal anaesthesia | oxygen therapeutics | clinical trials | Oxygen therapeutics | Haemoglobin-based oxygen carriers | Blood substitutes | Clinical trials | Haemoglobin | Spinal anaesthesia | HUMAN HEMOGLOBIN | MULTICENTER | DESIGN | SUBSTITUTES | TRANSPORT | haemoglobin-based oxygen carriers | POLYETHYLENE-GLYCOL | HEMATOLOGY | BLOOD | Single-Blind Method | Humans | Middle Aged | Isotonic Solutions - administration & dosage | Contrast Media - pharmacokinetics | Isotonic Solutions - adverse effects | Iohexol - pharmacokinetics | Male | Anesthesia, Spinal | Dose-Response Relationship, Drug | Time Factors | Orthopedic Procedures | Contrast Media - administration & dosage | Plasma Substitutes - administration & dosage | Adult | Female | Iohexol - administration & dosage | Aged | Blood Pressure - drug effects | Isotonic Solutions - pharmacokinetics | Cohort Studies | Plasma Substitutes - adverse effects | Plasma Substitutes - pharmacokinetics | Hospital patients | Surgery
MP4 | blood substitutes | haemoglobin | PEG | haemoglobin‐based oxygen carriers | spinal anaesthesia | oxygen therapeutics | clinical trials | Oxygen therapeutics | Haemoglobin-based oxygen carriers | Blood substitutes | Clinical trials | Haemoglobin | Spinal anaesthesia | HUMAN HEMOGLOBIN | MULTICENTER | DESIGN | SUBSTITUTES | TRANSPORT | haemoglobin-based oxygen carriers | POLYETHYLENE-GLYCOL | HEMATOLOGY | BLOOD | Single-Blind Method | Humans | Middle Aged | Isotonic Solutions - administration & dosage | Contrast Media - pharmacokinetics | Isotonic Solutions - adverse effects | Iohexol - pharmacokinetics | Male | Anesthesia, Spinal | Dose-Response Relationship, Drug | Time Factors | Orthopedic Procedures | Contrast Media - administration & dosage | Plasma Substitutes - administration & dosage | Adult | Female | Iohexol - administration & dosage | Aged | Blood Pressure - drug effects | Isotonic Solutions - pharmacokinetics | Cohort Studies | Plasma Substitutes - adverse effects | Plasma Substitutes - pharmacokinetics | Hospital patients | Surgery
Journal Article
American Journal of Emergency Medicine, ISSN 0735-6757, 2013, Volume 31, Issue 1, pp. 54 - 63
Abstract Background Plasma expander (PE) based on polyethylene glycol (PEG) conjugated to albumin has shown positive results maintaining blood volume during...
Emergency | HEMORRHAGIC-SHOCK | HEMOGLOBIN | PRESSURE | ARM FACILITATED PEGYLATION | EMERGENCY MEDICINE | CONDUCTANCE CATHETER | HUMAN SERUM-ALBUMIN | HEART-FAILURE | LOW-VISCOSITY | PEG-ALBUMIN | EXTREME HEMODILUTION | Cricetinae | Resuscitation - methods | Cardiac Output - drug effects | Ventricular Function, Left - drug effects | Plasma Substitutes - pharmacology | Blood Volume - drug effects | Male | Shock, Hemorrhagic - drug therapy | Hemodilution - methods | Cardiac Catheterization | Animals | Analysis of Variance | Serum Albumin - pharmacology | Mesocricetus | Vascular Resistance - drug effects | Polyethylene Glycols - pharmacology | Albumin | Polyols | Proteins | Heart | Studies | Plasma | Hypotheses | Rodents | Life sciences | Laboratory animals | Catheters | Molecular weight | Veins & arteries | resuscitation from hemorrhagic shock | conductance catheter | hemodilution | cardiac performance
Emergency | HEMORRHAGIC-SHOCK | HEMOGLOBIN | PRESSURE | ARM FACILITATED PEGYLATION | EMERGENCY MEDICINE | CONDUCTANCE CATHETER | HUMAN SERUM-ALBUMIN | HEART-FAILURE | LOW-VISCOSITY | PEG-ALBUMIN | EXTREME HEMODILUTION | Cricetinae | Resuscitation - methods | Cardiac Output - drug effects | Ventricular Function, Left - drug effects | Plasma Substitutes - pharmacology | Blood Volume - drug effects | Male | Shock, Hemorrhagic - drug therapy | Hemodilution - methods | Cardiac Catheterization | Animals | Analysis of Variance | Serum Albumin - pharmacology | Mesocricetus | Vascular Resistance - drug effects | Polyethylene Glycols - pharmacology | Albumin | Polyols | Proteins | Heart | Studies | Plasma | Hypotheses | Rodents | Life sciences | Laboratory animals | Catheters | Molecular weight | Veins & arteries | resuscitation from hemorrhagic shock | conductance catheter | hemodilution | cardiac performance
Journal Article
Seminars in thrombosis and hemostasis, ISSN 0094-6176, 2007, Volume 33, Issue 8, pp. 810 - 815
Patients with severe bleeding are often treated with colloids as plasma replacement fluids, including dextrans, gelatin-based solutions, or starches. Many of...
Plasma expanders | Dextrans | Plasma substitutes | Hemostasis | Coagulation | Starches | Fibrinolysis | Succinylated gelatin | Bleeding | plasma substitutes | bleeding | plasma expanders | BLOOD-COAGULATION | HYDROXYETHYL STARCH | PLATELET-FUNCTION | FACTOR-VIII | CARDIOPULMONARY BYPASS | hemostasis | coagulation | starches | fibrinolysis | CLOT FORMATION | ORTHOPEDIC-SURGERY | CARDIAC-SURGERY | MOLECULAR-WEIGHT HEPARIN | succinylated gelatin | dextrans | PERIPHERAL VASCULAR DISEASE | INTRAVASCULAR VOLUME | HEMATOLOGY | Plasma Substitutes - therapeutic use | Blood Platelets - metabolism | Gelatin - therapeutic use | Humans | Blood Coagulation | Hydroxyethyl Starch Derivatives - therapeutic use | Blood Coagulation Factors - metabolism | Dextrans - therapeutic use
Plasma expanders | Dextrans | Plasma substitutes | Hemostasis | Coagulation | Starches | Fibrinolysis | Succinylated gelatin | Bleeding | plasma substitutes | bleeding | plasma expanders | BLOOD-COAGULATION | HYDROXYETHYL STARCH | PLATELET-FUNCTION | FACTOR-VIII | CARDIOPULMONARY BYPASS | hemostasis | coagulation | starches | fibrinolysis | CLOT FORMATION | ORTHOPEDIC-SURGERY | CARDIAC-SURGERY | MOLECULAR-WEIGHT HEPARIN | succinylated gelatin | dextrans | PERIPHERAL VASCULAR DISEASE | INTRAVASCULAR VOLUME | HEMATOLOGY | Plasma Substitutes - therapeutic use | Blood Platelets - metabolism | Gelatin - therapeutic use | Humans | Blood Coagulation | Hydroxyethyl Starch Derivatives - therapeutic use | Blood Coagulation Factors - metabolism | Dextrans - therapeutic use
Journal Article
Indian Journal of Practical Pediatrics, ISSN 0972-9607, 10/2012, Volume 14, Issue 4, pp. 451 - 457
Journal Article
14.
Full Text
Carbohydrate plasma expanders for passive tumor targeting: In vitro and in vivo studies
Carbohydrate Polymers, ISSN 0144-8617, 06/2013, Volume 95, Issue 1, pp. 404 - 413
The objective of this study was to investigate the suitability of carbohydrate plasma volume expanders as a novel polymer platform for tumor targeting. Many...
Cytokine induction | Hydroxyethyl starch | Tumor accumulation | Multispectral optical imaging | HES | Passive tumor targeting | DRUG | ACTIVATION | POLYMER SCIENCE | CHEMISTRY, ORGANIC | BIODISTRIBUTION | RELEASE | POLYMER THERAPEUTICS | HPMA COPOLYMERS | NANOPARTICLES | PHARMACOKINETICS | ACCUMULATION | CHEMISTRY, APPLIED | HYDROXYETHYL STARCH HES | Leukocytes, Mononuclear - metabolism | Humans | Hydroxyethyl Starch Derivatives - pharmacokinetics | Dextrans - chemistry | Male | Colonic Neoplasms - metabolism | Dextrans - pharmacokinetics | Tissue Distribution | Plasma Substitutes - administration & dosage | Plasma Substitutes - chemistry | Female | Plasma Substitutes - pharmacokinetics | Cell Survival - drug effects | Leukocytes, Mononuclear - drug effects | Cytokines - metabolism | Hydroxyethyl Starch Derivatives - administration & dosage | Cells, Cultured | Hydroxyethyl Starch Derivatives - chemistry | Hep G2 Cells | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Mice, Nude | Colonic Neoplasms - pathology | Mice | Dextrans - administration & dosage | Dextran | Drugstores | Colon cancer | Tumors
Cytokine induction | Hydroxyethyl starch | Tumor accumulation | Multispectral optical imaging | HES | Passive tumor targeting | DRUG | ACTIVATION | POLYMER SCIENCE | CHEMISTRY, ORGANIC | BIODISTRIBUTION | RELEASE | POLYMER THERAPEUTICS | HPMA COPOLYMERS | NANOPARTICLES | PHARMACOKINETICS | ACCUMULATION | CHEMISTRY, APPLIED | HYDROXYETHYL STARCH HES | Leukocytes, Mononuclear - metabolism | Humans | Hydroxyethyl Starch Derivatives - pharmacokinetics | Dextrans - chemistry | Male | Colonic Neoplasms - metabolism | Dextrans - pharmacokinetics | Tissue Distribution | Plasma Substitutes - administration & dosage | Plasma Substitutes - chemistry | Female | Plasma Substitutes - pharmacokinetics | Cell Survival - drug effects | Leukocytes, Mononuclear - drug effects | Cytokines - metabolism | Hydroxyethyl Starch Derivatives - administration & dosage | Cells, Cultured | Hydroxyethyl Starch Derivatives - chemistry | Hep G2 Cells | Xenograft Model Antitumor Assays | Animals | Tumor Burden - drug effects | Mice, Nude | Colonic Neoplasms - pathology | Mice | Dextrans - administration & dosage | Dextran | Drugstores | Colon cancer | Tumors
Journal Article